Affimed to Present at Upcoming Investor Events

Rhea-AI Summary

Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company, announces upcoming presentations at investor conferences in February 2022. Key events include the SVB Leerink 2022 Global Healthcare Conference on February 16, 2022, at 11:20 a.m. EST, and Citi’s Virtual Immuno-Oncology Summit on February 17, 2022, at 2:30 p.m. EST. Both presentations will be available via webcast. The company aims to leverage its ROCK® platform for innovative tumor-targeted therapies, focusing on harnessing innate immune responses to fight various cancers.

HEIDELBERG, Germany, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that management will present and host one-on-one meetings at the following investor conferences during the month of February 2022.

11^th SVB Leerink 2022 Global Healthcare Conference (February 14 - 18, 2022)
Date: Wednesday, February 16, 2022
Presentation Time: 11:20 a.m. EST / 17:20 CET
Webcast: https://www.affimed.com/investors/webcasts-and-corporate-presentation/
Location: Virtual

Citi’s 2022 Virtual Immuno-Oncology Summit (February 17, 2022)
Date: Thursday, February 17, 2022
Presentation Time: 2:30 p.m. EST / 20:30 CET
Webcast: https://www.affimed.com/investors/webcasts-and-corporate-presentation/
Location: Virtual

For more information on the conferences or to schedule a one-on-one meeting with Affimed management, please contact your conference representative or Alex Fudukidis via email at a.fudukidis@affimed.com or phone at +1 (917) 436-8102.

About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company’s proprietary ROCK^® platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK^® platform predictably generates customized innate cell engager (ICE^®) molecules, which use patients’ immune cells to destroy tumor cells. This innovative approach enabled Affimed to become the first company with a clinical-stage ICE^®. Headquartered in Heidelberg, Germany, with offices in New York, NY, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by a bold vision to stop cancer from ever derailing patients’ lives. For more about the company’s people, pipeline and partners, please visit: https://www.affimed.com.

Affimed Investor Contact
Alexander Fudukidis

Director, Head of Investor Relations
E-Mail: a.fudukidis@affimed.com
Tel.: +1 (917) 436-8102

FAQ

What is the purpose of Affimed's presentations at the investor conferences in February 2022?

Affimed N.V. aims to present its innovative immuno-oncology strategies and engage with investors to discuss its pipeline at the upcoming conferences.

When is Affimed presenting at the SVB Leerink 2022 Global Healthcare Conference?

Affimed will present at the SVB Leerink 2022 Global Healthcare Conference on February 16, 2022, at 11:20 a.m. EST.

What is the presentation time for Affimed at Citi’s Virtual Immuno-Oncology Summit?

Affimed is scheduled to present at Citi’s Virtual Immuno-Oncology Summit on February 17, 2022, at 2:30 p.m. EST.

How can I access the webcasts for Affimed's investor presentations?

The webcasts for Affimed's presentations can be accessed at their investor relations website.

What is the focus of Affimed's ROCK® platform?

Affimed's ROCK® platform is designed to create tumor-targeted therapies that utilize the immune system to fight cancer, including hematologic and solid tumors.